TO Select a Novel Small Molecule Antibiotic for Clinical Development and Advance IT Through IND Filing and Phase 1 Clinical Studies
Contract Overview
Contract Amount: $26,944,787 ($26.9M)
Contractor: Revagenix Inc
Awarding Agency: Department of Health and Human Services
Start Date: 2020-07-01
End Date: 2026-08-31
Contract Duration: 2,252 days
Daily Burn Rate: $12.0K/day
Official Description: TO SELECT A NOVEL SMALL MOLECULE ANTIBIOTIC FOR CLINICAL DEVELOPMENT AND ADVANCE IT THROUGH IND FILING AND PHASE 1 CLINICAL STUDIES.
Place of Performance
Location: California, 92101